Literature DB >> 21539938

Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.

Yuxun Zhang1, Zhaojun Xie, Lirong Wang, Brielle Schreiter, John S Lazo, Jurg Gertsch, Xiang-Qun Xie.   

Abstract

W5.43(194), a conserved tryptophan residue among G-protein coupled receptors (GPCRs) and cannabinoid receptors (CB), was examined in the present report for its significance in CB2 receptor ligand binding and adenylyl cyclase (AC) activity. Computer modeling postulates that this site in CB2 may be involved in the affinity of WIN55212-2 and SR144528 through aromatic contacts. In the present study, we reported that a CB2 receptor mutant, W5.43(194)Y, which had a tyrosine (Y) substitution for tryptophan (W), retained the binding affinity for CB agonist CP55940, but reduced binding affinity for CB2 agonist WIN55212-2 and inverse agonist SR144528 by 8-fold and 5-fold, respectively; the CB2 W5.43(194)F and W5.43(194)A mutations significantly affect the binding activities of CP55940, WIN55212-2 and SR144528. Furthermore, we found that agonist-mediated inhibition of the forskolin-induced cAMP production was dramatically diminished in the CB2 mutant W5.43(194)Y, whereas W5.43(194)F and W5.43(194)A mutants resulted in complete elimination of downstream signaling, suggesting that W5.43(194) was essential for the full activation of CB2. These results indicate that both aromatic interaction and hydrogen bonding are involved in ligand binding for the residue W5.43(194), and the mutations of this tryptophan site may affect the conformation of the ligand binding pocket and therefore control the active conformation of the wild type CB2 receptor. W5.43(194)Y/F/A mutations also displayed noticeable enhancement of the constitutive activation probably attributed to the receptor conformational changes resulted from the mutations.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21539938      PMCID: PMC3445262          DOI: 10.1016/j.intimp.2011.04.013

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  35 in total

1.  3D structural model of the G-protein-coupled cannabinoid CB2 receptor.

Authors:  Xiang-Qun Xie; Jian-Zhong Chen; Eric M Billings
Journal:  Proteins       Date:  2003-11-01

2.  Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.

Authors:  M Bouaboula; N Desnoyer; P Carayon; T Combes; P Casellas
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

3.  Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.

Authors:  M Glass; C C Felder
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

4.  SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.

Authors:  M Portier; M Rinaldi-Carmona; F Pecceu; T Combes; C Poinot-Chazel; B Calandra; F Barth; G le Fur; P Casellas
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

5.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

Authors:  S Galiègue; S Mary; J Marchand; D Dussossoy; D Carrière; P Carayon; M Bouaboula; D Shire; G Le Fur; P Casellas
Journal:  Eur J Biochem       Date:  1995-08-15

6.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.

Authors:  P Samama; S Cotecchia; T Costa; R J Lefkowitz
Journal:  J Biol Chem       Date:  1993-03-05       Impact factor: 5.157

7.  Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

Authors:  P Gouldson; B Calandra; P Legoux; A Kernéis; M Rinaldi-Carmona; F Barth; G Le Fur; P Ferrara; D Shire
Journal:  Eur J Pharmacol       Date:  2000-07-28       Impact factor: 4.432

8.  Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.

Authors:  M Bouaboula; C Poinot-Chazel; J Marchand; X Canat; B Bourrié; M Rinaldi-Carmona; B Calandra; G Le Fur; P Casellas
Journal:  Eur J Biochem       Date:  1996-05-01

9.  Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes.

Authors:  M H Rhee; M Bayewitch; T Avidor-Reiss; R Levy; Z Vogel
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

10.  Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells.

Authors:  Cristina Zoratti; Dijle Kipmen-Korgun; Karin Osibow; Roland Malli; Wolfgang F Graier
Journal:  Br J Pharmacol       Date:  2003-11-24       Impact factor: 8.739

View more
  19 in total

1.  Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.

Authors:  Chloe J Jordan; Zhi-Wei Feng; Ewa Galaj; Guo-Hua Bi; Ying Xue; Ying Liang; Terence McGuire; Xiang-Qun Xie; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

2.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

3.  Mastering tricyclic ring systems for desirable functional cannabinoid activity.

Authors:  Ravil R Petrov; Lindsay Knight; Shao-Rui Chen; Jim Wager-Miller; Steven W McDaniel; Fanny Diaz; Francis Barth; Hui-Lin Pan; Ken Mackie; Claudio N Cavasotto; Philippe Diaz
Journal:  Eur J Med Chem       Date:  2013-09-29       Impact factor: 6.514

4.  CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.

Authors:  Reem Smoum; Saja Baraghithy; Mukesh Chourasia; Aviva Breuer; Naama Mussai; Malka Attar-Namdar; Natalya M Kogan; Bitya Raphael; Daniele Bolognini; Maria G Cascio; Pietro Marini; Roger G Pertwee; Avital Shurki; Raphael Mechoulam; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

5.  Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.

Authors:  Changrui Xing; Youwen Zhuang; Ting-Hai Xu; Zhiwei Feng; X Edward Zhou; Maozi Chen; Lei Wang; Xing Meng; Ying Xue; Junmei Wang; Heng Liu; Terence Francis McGuire; Gongpu Zhao; Karsten Melcher; Cheng Zhang; H Eric Xu; Xiang-Qun Xie
Journal:  Cell       Date:  2020-01-30       Impact factor: 41.582

6.  Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.

Authors:  Mohammed Alqarni; Kyaw Zeyar Myint; Qin Tong; Peng Yang; Patrick Bartlow; Lirong Wang; Rentian Feng; Xiang-Qun Xie
Journal:  Biochem Biophys Res Commun       Date:  2014-08-19       Impact factor: 3.575

7.  Selective Cannabinoid 2 Receptor Stimulation Reduces Tubular Epithelial Cell Damage after Renal Ischemia-Reperfusion Injury.

Authors:  Jeffrey D Pressly; Suni M Mustafa; Ammaar H Adibi; Sahar Alghamdi; Pankaj Pandey; Kuldeep K Roy; Robert J Doerksen; Bob M Moore; Frank Park
Journal:  J Pharmacol Exp Ther       Date:  2017-11-29       Impact factor: 4.030

8.  Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions.

Authors:  Kyaw-Zeyar Myint; Lirong Wang; Qin Tong; Xiang-Qun Xie
Journal:  Mol Pharm       Date:  2012-08-31       Impact factor: 4.939

9.  Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

Authors:  Peng Yang; Kyaw-Zeyar Myint; Qin Tong; Rentian Feng; Haiping Cao; Abdulrahman A Almehizia; Mohammed Hamed Alqarni; Lirong Wang; Patrick Bartlow; Yingdai Gao; Jürg Gertsch; Jumpei Teramachi; Noriyoshi Kurihara; Garson David Roodman; Tao Cheng; Xiang-Qun Xie
Journal:  J Med Chem       Date:  2012-10-31       Impact factor: 7.446

10.  Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Authors:  Jianping Hu; Zhiwei Feng; Shifan Ma; Yu Zhang; Qin Tong; Mohammed Hamed Alqarni; Xiaojun Gou; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2016-05-26       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.